CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma
To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.
Non Hodgkin Lymphoma
BIOLOGICAL: CD19 CAR-T cells infusion
BORR, Best objective response rate, 6 months
Incidence of AE, Incidence of adverse reactions, 2 years|Pharmacokinetic parameters, the area under the curve of 28 days AUC0-28d and 90 days AUC0-90d of targeting CD19 chimeric antigen receptor T cells in peripheral blood after administration, 90 Days|Overall survival time, Overall survival time, through study completion, an average of 5 year|Duration of remission after administration, Duration of remission after administration, through study completion, an average of 5 year|Disease progression free survival, Disease progression free survival, through study completion, an average of 5 year
To evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor T cell infusion in the treatment of relapsed or refractory CD19 positive non-Hodgkin's lymphoma.